← All trials
NCT03357653
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2018
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 174
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ewha Womans UniversityLead sponsor
- Ajou UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Korea UniversityCollaborator
- Kyung Hee UniversityCollaborator
- Catholic University of KoreaCollaborator
- Seoul National UniversityCollaborator
- Eulji UniversityCollaborator
- Hallym UniversityCollaborator
- Yonsei UniversityCollaborator
- Ewha Womans UniversityOverall official - principal investigator
- Chonnam National UniversityCollaborator
- Kyungpook UniversityCollaborator
- Ilsan HospitalCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.